**Zydus Lifesciences Expands Biologics Manufacturing with Agenus Acquisition**
Zydus Lifesciences has announced its acquisition of two biologics contract manufacturing facilities in California from Agenus Inc., a US-based company, for a total of up to $125 million. The deal includes an initial payment of $75 million, with an additional $50 million to be paid over the next three years, contingent on achieving specific revenue milestones. This strategic move is aimed at establishing Zydus’s presence in the rapidly growing global biologics contract development and manufacturing organization (CDMO) sector.
In addition to the facilities, Zydus is acquiring a 5.9% stake in Agenus for $16 million through its wholly-owned subsidiary, Zynext Ventures USA LLC. The pharmaceutical firm has also entered into a licensing agreement with Agenus to commercialize its investigational therapies, Botensilimab (BOT) and Balstilimab (BAL), in India and Sri Lanka. Agenus is recognized for its commitment to developing immune therapies for cancer treatment.
Managing Director Sharvil Patel emphasized that this acquisition will provide Zydus with a strategic foothold in California, a global hub for biotech innovation. He stated, “This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry.” The acquisition also enhances Zydus’s manufacturing capabilities in the US, especially amid uncertainties regarding potential tariffs on pharmaceutical imports.
The agreement includes the acquisition of modern biologics manufacturing facilities located in Emeryville and Berkeley, California. This will grant Zydus immediate access to advanced manufacturing capabilities and allow the company to leverage supply chain dynamics and a favorable geopolitical environment to expand its reach both in the US and globally. The CDMO business will operate independently, housing the newly acquired manufacturing capabilities.
As part of the transaction, Zydus will become the exclusive contract manufacturer for Agenus, providing manufacturing services for two identified Phase-3 ready immuno-oncology products.
**FAQ**
*What is the significance of Zydus Lifesciences’ acquisition of Agenus facilities?*
The acquisition allows Zydus to enhance its biologics manufacturing capabilities, establish a presence in a key biotech hub, and better serve the global biopharmaceutical market.
